AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Hutchinson-Gilford Progeria Syndrome

Recent research efforts aimed at curing Hutchinson-Gilford Progeria Syndrome.

Last updated

Hutchinson-Gilford Progeria Syndrome

Overview

Hutchinson-Gilford Progeria Syndrome (HGPS, or progeria) is an exceptionally rare genetic condition, usually caused by a new (not inherited) change in the LMNA gene. The change produces progerin, an abnormal version of the structural protein lamin A, which progressively damages cells. Children generally appear healthy at birth but develop poor growth, loss of body fat and hair, skin and joint changes, and severe early hardening of the arteries; intelligence is typically unaffected. MedlinePlus Genetics overview

The major life-threatening problems are heart attack and stroke caused by childhood-onset cardiovascular disease. Without lonafarnib, average survival is about 14.5 years; GeneReviews estimates that treatment extends average survival to about 18.7 years. Current care combines the oral farnesyltransferase inhibitor lonafarnib (Zokinvy), cardiovascular monitoring and treatment, nutrition and physical support, and multidisciplinary management. Lonafarnib reduces mortality risk but does not repair the causal LMNA mutation. GeneReviews: HGPS Zokinvy prescribing information

Scope of Recent Research (2020–present)

The field is small because HGPS affects roughly one in four million newborns, but it is scientifically active and increasingly focused on stopping progerin at its source: correcting the DNA mutation, preventing the abnormal RNA message, or removing the toxic protein. A genuine curative strategy is plausible in principle because most classic cases share the same single-letter LMNA variant, but as of October 18, 2026, no gene- or RNA-based therapy has demonstrated safety and durable clinical benefit in people with HGPS. MedlinePlus Genetics overview PRF Path to Cure initiative

Major Breakthroughs and Emerging Therapies

DNA base editing is the leading potentially curative approach. Base editing is a CRISPR-derived technique that chemically converts one DNA “letter” to another without deliberately cutting both DNA strands. In a landmark 2021 study, an adenine base editor corrected the typical HGPS mutation in 87–91% of treated patient fibroblasts and, after one AAV9 viral-vector injection in mice, improved vascular disease and increased median survival from 215 to 510 days. In vivo base editing in HGPS mice Follow-up work published in September 2026 found that AAV9-delivered base editing also partially corrected bone abnormalities in HGPS-model mice, but showed that editing efficiency in bone fell sharply when treatment was given later—an important warning that timing and tissue delivery will matter in children. Base editing and bone dysplasia

The Progeria Research Foundation (PRF) is advancing a candidate called SamPro-2, an AAV9-packaged in vivo base-editing therapy intended to permanently correct the common causal DNA change. In March 2026, PRF announced a manufacturing partnership with Forge Biologics; the program remained preclinical, focused on clinical-grade manufacturing, regulatory engagement, and trial preparation rather than human dosing. SamPro-2 manufacturing announcement PRF Path to Cure initiative

RNA-directed therapies seek to prevent production of progerin without permanently changing DNA. A 2021 systematic screen of 198 antisense oligonucleotides—short synthetic strands designed to alter RNA processing—identified compounds that reduced progerin RNA and extended lifespan in an HGPS mouse model, although protein reduction varied by tissue. Antisense oligonucleotide screen In 2025, researchers reported that RfxCas13d, an RNA-targeting CRISPR enzyme, selectively reduced progerin messenger RNA while preserving normal lamin A in cells and improved disease-like features in mice. RfxCas13d progerin targeting A further 2026 organoid study described “FATE,” a mutation-independent base-editing concept aimed at disabling progerin’s farnesylation site; lipid-nanoparticle delivery of editor mRNA rescued molecular abnormalities in human neuromuscular organoids, but this remains an early laboratory result. FATE editing in neuromuscular organoids

Small-molecule strategies remain important as near-term treatments and possible combination partners. Progerinin was designed to interfere with binding between progerin and lamin A; preclinical work reported improvement in cellular and mouse measures of premature aging. Progerinin preclinical study Other experimental approaches attempt to lower progerin toxicity or enhance its clearance. For example, selinexor improved cellular markers, reduced progerin in several mouse tissues, and improved aortic pathology in an HGPS mouse model, but it has not been established as an HGPS treatment in people. Selinexor/CRM1 study

Clinical Trials and Experimental Approaches

The principal active interventional HGPS study listed as of October 18, 2026 is NCT06775041, a Phase 2a, randomized, open-label trial of progerinin plus lonafarnib versus lonafarnib alone. It is sponsored by PRG Science & Technology, began on January 13, 2025, enrolled 10 participants, and was listed as active but not recruiting in the registry’s February 9, 2026 update. Its primary aims are dose selection, safety, tolerability, and pharmacokinetics; no trial results had been posted. NCT06775041 trial record

Lonafarnib is the current approved disease-targeted therapy, not a cure. It is indicated in the United States for people aged 12 months and older who meet body-surface-area requirements to reduce mortality risk in HGPS, but it requires ongoing dosing and monitoring for gastrointestinal effects, drug interactions, laboratory abnormalities, kidney risk, and eye toxicity. Zokinvy prescribing information

Methodologies and Scientific Approaches

Researchers use patient-derived fibroblasts, induced pluripotent stem-cell models, organoids, and genetically engineered mouse models to measure whether an intervention reduces progerin, restores normal nuclear shape, improves DNA repair and gene expression, and prevents vascular, bone, or metabolic damage. The most decisive preclinical readouts are survival, aortic structure, vascular smooth-muscle preservation, bone strength, and tissue-specific correction of the pathogenic LMNA sequence. In vivo base editing in HGPS mice Base editing and bone dysplasia FATE editing in neuromuscular organoids

Delivery is a central experimental variable. AAV9 vectors can reach several relevant organs after intravenous administration, while antisense, Cas13, and mRNA-editor approaches may offer temporary or repeatable RNA-level intervention. Researchers must measure editing accuracy, unintended DNA or RNA changes, immune reactions, durability, and whether enough cells are reached in the aorta, heart, bone, skin, and other tissues that drive disease. In vivo base editing in HGPS mice Antisense oligonucleotide screen RfxCas13d progerin targeting

Leading Institutions and Funding

Key contributors include the National Human Genome Research Institute at NIH, the Broad Institute of MIT and Harvard, Harvard Medical School-affiliated groups, Boston Children’s Hospital, the Progeria Research Foundation, and clinical collaborators supporting the international HGPS community. The original in vivo base-editing work brought together NIH, the Broad Institute, Vanderbilt University Medical Center, and PRF; the 2026 bone study included NIH, the Broad Institute, Harvard affiliates, and PRF. NIH base-editing research announcement Base editing and bone dysplasia

PRF is the principal disease-focused philanthropic organization and is coordinating the Path to Cure Progeria program, while Forge Biologics is supporting AAV manufacturing for SamPro-2. Publicly reported HGPS research support includes PRF grant programs such as PRF 2021-78 and PRF 2022-84, alongside national funding bodies and disease-research infrastructure; published sources do not consistently disclose grant dollar amounts. PRF Path to Cure initiative SamPro-2 manufacturing announcement PROTAC study funding statement

Strengths, Limitations, and Challenges

The strongest rationale for cure is unusually clear: classic HGPS is commonly driven by one recurrent DNA change, and correcting that change has produced large survival and vascular benefits in mice. RNA approaches also provide potentially safer, reversible ways to lower progerin while preserving normal lamin A. In vivo base editing in HGPS mice RfxCas13d progerin targeting

The gap between promising mouse data and a human cure remains substantial. HGPS damages many organs, so a one-time therapy must reach enough relevant cells safely and early enough; recent bone data show incomplete correction and a strong dependence on treatment age. Permanent DNA editing also requires extensive assessment of unintended edits, immune responses, vector dose, repeat-dosing limitations, and years of follow-up. Meanwhile, lonafarnib improves survival but has clinically significant adverse effects and does not eliminate progerin production. Base editing and bone dysplasia Zokinvy prescribing information

Outlook and Future Directions

HGPS is closer to a biologically credible cure than it was in 2020, but it is not yet close to a proven human cure. The key milestones to watch are completion and reporting of the progerinin Phase 2a study; release of SamPro-2 manufacturing, toxicology, and regulatory progress; authorization of a first-in-human editing study; and evidence that a therapy can safely reduce progerin and improve cardiovascular outcomes across multiple tissues in people. Until then, lonafarnib plus expert supportive care remains the standard, while gene editing and RNA therapies should be understood as high-potential experimental programs rather than available cures. NCT06775041 trial record PRF Path to Cure initiative GeneReviews: HGPS

References

Don't see your disease? Request a report